VerifyMe jumps 13%, to get $4.7M from warrant exercise
[ad_1]
VerifyMe jumps 13%, to get $4.7M from warrant exercise
[ad_2]
[ad_1] Las Vegas Sands falls after Morgan Stanley says valuation already reflects upside [ad_2]
[ad_1] RBC Target 2027 U.S. Corporate Bond ETF declares $0.033 dividend [ad_2]
[ad_1] JPMorgan BetaBuilders Developed Asia Pacific ex-Japan ETF declares quarterly distribution of $0.3901 [ad_2]
[ad_1] Most and least shorted S&P 500 financial stocks in December [ad_2]
[ad_1] YinYang REGENXBIO (NASDAQ:RGNX) and Nippon Shinyaku have entered into a partnership for the development and commercialization of REGENXBIO’s gene therapies RGX-121 for the treatment of Hunter syndrome, or MPS II, and RGX-111 for Hurler syndrome, or MPS I. Under the deal, REGENXBIO ( [ad_2]
[ad_1] From misinformation threats to restoring free expression: Inside Meta's latest moves [ad_2]